The group with CD19(+)CD5(+) B cells > 0.03 × 109 /L also had better survival in the total cohort (67.27 ± 4.55 vs. 89.11 ± 3.65 months, P = 0.001, Fig. 3E) and CKD group (57.83 ± 5.35 vs. 81.43 ± 4.80 months, P = 0.002, Fig. 3F). This evidence concerns the gene CD5 and chronic kidney disease.